111 related articles for article (PubMed ID: 27106063)
1. Mutation analysis of the PALB2 gene in unselected pancreatic cancer patients in the Czech Republic.
Borecka M; Zemankova P; Vocka M; Soucek P; Soukupova J; Kleiblova P; Sevcik J; Kleibl Z; Janatova M
Cancer Genet; 2016 May; 209(5):199-204. PubMed ID: 27106063
[TBL] [Abstract][Full Text] [Related]
2. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene.
Jones S; Hruban RH; Kamiyama M; Borges M; Zhang X; Parsons DW; Lin JC; Palmisano E; Brune K; Jaffee EM; Iacobuzio-Donahue CA; Maitra A; Parmigiani G; Kern SE; Velculescu VE; Kinzler KW; Vogelstein B; Eshleman JR; Goggins M; Klein AP
Science; 2009 Apr; 324(5924):217. PubMed ID: 19264984
[TBL] [Abstract][Full Text] [Related]
3. Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma.
Connor AA; Denroche RE; Jang GH; Timms L; Kalimuthu SN; Selander I; McPherson T; Wilson GW; Chan-Seng-Yue MA; Borozan I; Ferretti V; Grant RC; Lungu IM; Costello E; Greenhalf W; Palmer D; Ghaneh P; Neoptolemos JP; Buchler M; Petersen G; Thayer S; Hollingsworth MA; Sherker A; Durocher D; Dhani N; Hedley D; Serra S; Pollett A; Roehrl MHA; Bavi P; Bartlett JMS; Cleary S; Wilson JM; Alexandrov LB; Moore M; Wouters BG; McPherson JD; Notta F; Stein LD; Gallinger S
JAMA Oncol; 2017 Jun; 3(6):774-783. PubMed ID: 27768182
[TBL] [Abstract][Full Text] [Related]
4. Molecular characteristics of
Seeber A; Zimmer K; Kocher F; Puccini A; Xiu J; Nabhan C; Elliott A; Goldberg RM; Grothey A; Shields AF; Battaglin F; El-Deiry WS; Philip PA; Marshall JL; Hall M; Korn WM; Lenz HJ; Wolf D; Feistritzer C; Spizzo G
ESMO Open; 2020 Nov; 5(6):e000942. PubMed ID: 33229504
[TBL] [Abstract][Full Text] [Related]
5. Breast-cancer risk in families with mutations in PALB2.
Antoniou AC; Casadei S; Heikkinen T; Barrowdale D; Pylkäs K; Roberts J; Lee A; Subramanian D; De Leeneer K; Fostira F; Tomiak E; Neuhausen SL; Teo ZL; Khan S; Aittomäki K; Moilanen JS; Turnbull C; Seal S; Mannermaa A; Kallioniemi A; Lindeman GJ; Buys SS; Andrulis IL; Radice P; Tondini C; Manoukian S; Toland AE; Miron P; Weitzel JN; Domchek SM; Poppe B; Claes KB; Yannoukakos D; Concannon P; Bernstein JL; James PA; Easton DF; Goldgar DE; Hopper JL; Rahman N; Peterlongo P; Nevanlinna H; King MC; Couch FJ; Southey MC; Winqvist R; Foulkes WD; Tischkowitz M
N Engl J Med; 2014 Aug; 371(6):497-506. PubMed ID: 25099575
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and Risk Factors of Germline Pathogenic Variants in Pancreatic Ductal Adenocarcinoma.
Ryu KH; Park S; Chun JW; Cho E; Choi J; Lee DE; Shim H; Kim YH; Han SS; Park SJ; Woo SM; Kong SY
Cancer Res Treat; 2023 Oct; 55(4):1303-1312. PubMed ID: 37024097
[TBL] [Abstract][Full Text] [Related]
7. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer.
Yurgelun MB; Chittenden AB; Morales-Oyarvide V; Rubinson DA; Dunne RF; Kozak MM; Qian ZR; Welch MW; Brais LK; Da Silva A; Bui JL; Yuan C; Li T; Li W; Masuda A; Gu M; Bullock AJ; Chang DT; Clancy TE; Linehan DC; Findeis-Hosey JJ; Doyle LA; Thorner AR; Ducar MD; Wollison BM; Khalaf N; Perez K; Syngal S; Aguirre AJ; Hahn WC; Meyerson ML; Fuchs CS; Ogino S; Hornick JL; Hezel AF; Koong AC; Nowak JA; Wolpin BM
Genet Med; 2019 Jan; 21(1):213-223. PubMed ID: 29961768
[TBL] [Abstract][Full Text] [Related]
8. Surveillance Outcome and Genetic Findings in Individuals at High Risk of Pancreatic Cancer.
Rosner G; Scapa E; Ziv T; Gluck N; Ben-Yehoyada M
Clin Transl Gastroenterol; 2024 Feb; 15(2):e00668. PubMed ID: 38147532
[TBL] [Abstract][Full Text] [Related]
9. Significant detection of new germline pathogenic variants in Australian Pancreatic Cancer Screening Program participants.
Murali K; Dwarte TM; Nikfarjam M; Tucker KM; Vaughan RB; Efthymiou M; Collins A; Spigelman AD; Salmon L; Johns AL; Williams DB; Delatycki MB; John T; Stoita A
Hered Cancer Clin Pract; 2021 Aug; 19(1):33. PubMed ID: 34399810
[TBL] [Abstract][Full Text] [Related]
10. Gene-Level Associations in Patients With and Without Pathogenic Germline Variants in
Astiazaran-Symonds E; Graham C; Kim J; Tucker MA; Ingvar C; Helgadottir H; Pastorino L; van Doorn R; Sampson JN; Zhu B; Bruno W; Queirolo P; Fornarini G; Sciallero S; Carter B; Hicks B; Hutchinson A; Jones K; Stewart DR; Chanock SJ; Freedman ND; Landi MT; Höiom V; Puig S; Gruis N; Yang XR; Ghiorzo P; Goldstein AM
JCO Precis Oncol; 2022 Nov; 6():e2200145. PubMed ID: 36409970
[TBL] [Abstract][Full Text] [Related]
11. Germline sequence analysis of RABL3 in a large series of pancreatic ductal adenocarcinoma patients reveals no evidence of deleterious variants.
Roberts NJ; Grant RC; Gallinger S; Klein AP;
Genes Chromosomes Cancer; 2021 Aug; 60(8):559-564. PubMed ID: 33724601
[TBL] [Abstract][Full Text] [Related]
12. Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC.
Florou V; Elliott A; Bailey MH; Stone D; Affolter K; Soares HP; Nevala-Plagemann C; Scaife C; Walker P; Korn WM; Lou E; Shroff RT; Hosein PJ; Garrido-Laguna I
Clin Cancer Res; 2023 Sep; 29(17):3408-3417. PubMed ID: 37266563
[TBL] [Abstract][Full Text] [Related]
13. Genetic testing to guide screening for pancreatic ductal adenocarcinoma: Results of a microsimulation model.
Peters MLB; Eckel A; Lietz A; Seguin C; Mueller P; Hur C; Pandharipande PV
Pancreatology; 2022 Sep; 22(6):760-769. PubMed ID: 35752568
[TBL] [Abstract][Full Text] [Related]
14. Long-term yield of pancreatic cancer surveillance in high-risk individuals.
Overbeek KA; Levink IJM; Koopmann BDM; Harinck F; Konings ICAW; Ausems MGEM; Wagner A; Fockens P; van Eijck CH; Groot Koerkamp B; Busch ORC; Besselink MG; Bastiaansen BAJ; van Driel LMJW; Erler NS; Vleggaar FP; Poley JW; Cahen DL; van Hooft JE; Bruno MJ;
Gut; 2022 Jun; 71(6):1152-1160. PubMed ID: 33820756
[TBL] [Abstract][Full Text] [Related]
15. Tissue methylated DNA markers for sporadic pancreatic cancer are strongly associated with familial and genetically predisposed pancreatic cancer.
Majumder S; Taylor WR; Foote PH; Gysbers BJ; Cao X; Mahoney DW; Burger KN; Doering KA; Graham RP; Couch FJ; Petersen GM; Kisiel JB
Pancreatology; 2022 Sep; 22(6):770-773. PubMed ID: 35843766
[TBL] [Abstract][Full Text] [Related]
16. Germline
Kwong A; Shin VY; Ho CYS; Khalid A; Au CH; Chan KKL; Ngan HYS; Chan TL; Ma ESK
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439348
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of familial pancreatic cancer families with additional colorectal carcinoma.
Lehman B; Matthäi E; Gercke N; Denzer UW; Figiel J; Hess T; Slater EP; Bartsch DK
Fam Cancer; 2023 Jul; 22(3):323-330. PubMed ID: 36717525
[TBL] [Abstract][Full Text] [Related]
18. Understanding the Genetic Landscape of Pancreatic Ductal Adenocarcinoma to Support Personalized Medicine: A Systematic Review.
Pantaleo A; Forte G; Fasano C; Lepore Signorile M; Sanese P; De Marco K; Di Nicola E; Latrofa M; Grossi V; Disciglio V; Simone C
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201484
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a germline variant TNS1 c.2999-1G > C in a hereditary cancer syndrome family.
Di X; Wang D; Wu J; Zhu X; Wang Y; Yan J; Wen L; Jiang H; Wen D; Shu B; Zhang S
Gene; 2024 May; 908():148304. PubMed ID: 38387708
[TBL] [Abstract][Full Text] [Related]
20. Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms.
Obazee O; Capurso G; Tavano F; Archibugi L; De Bonis A; Greenhalf W; Key T; Pasquali C; Milanetto AC; Hackert T; Fogar P; Liço V; Dervenis C; Lawlor RT; Landoni L; Gazouli M; Zambon CF; Funel N; Strobel O; Jamroziak K; Cantù C; Malecka-Panas E; Landi S; Neoptolemos JP; Basso D; Talar-Wojnarowska R; Rinzivillo M; Andriulli A; Canzian F; Campa D
Carcinogenesis; 2018 Mar; 39(3):360-367. PubMed ID: 29309705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
